Lifor
Developer and producer of a next-generation, synthetic serum-free preservation solution for cells, tissues and organs. Focus areas include formulation of temperature-tolerant preservation fluids, nano-carrier–based approaches to enhance tissue oxygenation, preclinical evaluation in large-animal models, cryopreservation research, and analytical testing to support diagnostic and transport applications. The site describes ongoing testing, patent activity, and comparative preclinical studies.
Industries
Nr. of Employees
small (1-50)
Products
Next-generation preservation solution for cells, tissues and organs
A synthetic, serum-free preservation fluid intended to extend viability of cells, tissues and organs during storage and transport while minimizing cellular damage and the need for fixatives.
Next-generation preservation solution for cells, tissues and organs
A synthetic, serum-free preservation fluid intended to extend viability of cells, tissues and organs during storage and transport while minimizing cellular damage and the need for fixatives.
Services
Design and execution of preclinical studies and analytical testing to assess preservation formulations and protocols.
Design and execution of preclinical studies and analytical testing to assess preservation formulations and protocols.
Expertise Areas
- Organ and tissue preservation
- Cryopreservation
- Biomaterial and reagent formulation
- Preclinical large-animal studies
Key Technologies
- Liposome-based oxygen nano-carriers
- Synthetic serum-free preservation formulations
- Room-temperature preservation techniques
- Cryopreservation methods
News & Updates
A congressional earmark grant was approved (timeline entry).
Performed a baboon kidney study in collaboration with a U.S. naval medical group (timeline entry).
Performed a limb preservation study in swine (timeline entry).
Reported transition of the formulation to an all protein/serum-free composition (timeline entry).
Initiated investigations into fluid-replacement approaches for preservation (timeline entry).
Completed first proof-of-principle study for a fluid-replacement approach (timeline entry).
A congressional earmark grant was approved (timeline entry).
Performed a baboon kidney study in collaboration with a U.S. naval medical group (timeline entry).
Performed a limb preservation study in swine (timeline entry).
Reported transition of the formulation to an all protein/serum-free composition (timeline entry).
Initiated investigations into fluid-replacement approaches for preservation (timeline entry).
Completed first proof-of-principle study for a fluid-replacement approach (timeline entry).